Helixmith Co. Ltd (084990) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Helixmith Co. Ltd KRW 774, price KRW 2,995, upside -74.2%, quality 50 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Helixmith Co. Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 2,185 KRW – 36,273 KRW · fair‑value band 756.32 KRW – 802.73 KRW · the 2,995 KRW price screens above the 774.11 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Helixmith Co. in your weekly email
Every Wednesday you see whether Helixmith Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Helixmith Co., Ltd, a biotechnology company, discovers and develops biopharmaceuticals for human diseases. The company has a pipeline of novel biologics and herbal therapeutics in the areas of cardiovascular disease, cancer, and immune disorder, with clinical studies ongoing in the United States, Korea, and China.
Show more
Helixmith Co., Ltd, a biotechnology company, discovers and develops biopharmaceuticals for human diseases. The company has a pipeline of novel biologics and herbal therapeutics in the areas of cardiovascular disease, cancer, and immune disorder, with clinical studies ongoing in the United States, Korea, and China. Its flagship product is VM202, a DNA-based drug for cardiovascular and neurological diseases. The company's pipeline products include VM206, a therapeutic cancer vaccine targeting HER2/neu positive breast or ovarian cancer; and VM501, a re-engineered form of interleukin 11 targeting chemotherapy-induced thrombocytopenia. Its clinical trials biologics comprise VM202-DPN, VM202-PAD, VM501, VM202-ALS, VM202-CAD, and VM206. The company was formerly known as ViroMed Co., Ltd. and changed its name to Helixmith Co., Ltd in April 2019. Helixmith Co., Ltd was incorporated in 1996 and is headquartered in Seoul, South Korea.
Stock analysis
Helixmith Co. Ltd (084990) currently trades at 2,995 KRW, while our model-based Fair Value estimate is 774.11 KRW, implying the stock looks roughly 286.8% overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 2 models at a data quality of 94/100, which puts the evidence level at low.
Scenario range: 756.32 KRW (bear) to 802.73 KRW (bull), the price of 2,995 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 50/100 (solid quality), in the Consumer Non-Cyclicals sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Helixmith Co. Ltd reported revenue of 2.6B KRW in FY2025 versus 2.3B KRW in FY2021, a compound +2.9%/yr. Reported net income was −435M KRW in FY2025.
Key figures
Market cap 158B KRW (≈ $110M) · P/S ratio 54.5 · Net margin −16.7% · Return on equity −803% · Return on assets (EBIT) −21.2% · Operating margin −1,924% · Revenue (TTM) 2.9B KRW · Revenue growth (YoY) +18.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 34 out of 100 (medium confidence).
What moves the price
The share trades about 68% below its 52-week high and 7% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Consumer Non-Cyclicals peers we cover trades at −10% fair-value upside, at −74%, 084990 screens richer than that median.
Fair Value models
Bear 756.32 KRWFair Value 774.11 KRWBull 802.73 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−47.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−9.6%
Start year 2020 (pandemic). Over 10 years: −10.3% a year
Revenue growth 15 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−3.8%
’13
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1,700.1% (2020) → −380.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Food & Tobacco · 24 stocks
Beats the industry median on 2/6 measures
Overall it trails its industry peers.
Valuation
Quality Score50 · Below median
Fair Value upside−74% · Bottom 25%
Profitability
Return on assets−12% · Bottom 25%
Net margin (TTM)−17% · Bottom 25%
Growth and dividend
Revenue growth18% · Top 25%
Balance sheet
Debt / equity0.00× · Below median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 56
FUTURE (revenue growth)91· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)100· sector 97
DIVIDEND (yield)0· sector 63
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Helixmith Co. Ltd (084990) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 774.11 KRW versus a price of 2,995 KRW, about −74% upside (overvalued).
What is the fair value of 084990?
Our model-based fair value for Helixmith Co. Ltd is 774.11 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 2,995 KRW.
What is the quality score of 084990?
Helixmith Co. Ltd has a Quality Score of 50/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Helixmith Co. Ltd (084990)?
Our model-based price target is the fair value of 774.11 KRW (as of Sep 24, 2026) from 2 valuation models. Cautious scenario 756.32 KRW, optimistic scenario 802.73 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Helixmith Co. Ltd stock forecast for 2026?
Our models put fair value at 774.11 KRW, about −74% upside versus a price of 2,995 KRW (overvalued). Cautious scenario 756.32 KRW, optimistic scenario 802.73 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Helixmith Co. Ltd (084990)?
Helixmith Co. Ltd reported trailing-twelve-month revenue of about 2.9B KRW (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Helixmith Co. Ltd (084990)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Helixmith Co. Ltd it is 774.11 KRW per share (as of Sep 24, 2026), against a price of 2,995 KRW. It is the blended result of 2 valuation models (cash flow, earnings, asset, dividend).
Is Helixmith Co. Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 084990 trades above its calculated fair value: price 2,995 KRW, fair value 774.11 KRW, a gap of about −74% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 084990?
No. The price is what the market pays today (2,995 KRW); the fair value is what the company's own numbers justify (774.11 KRW). For Helixmith Co. Ltd the two are 2,221 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Helixmith Co. Ltd worth?
The market values Helixmith Co. Ltd at about 158B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 2,995 KRW; our models calculate a fair value of 774.11 KRW per share.
What do the bullish and bearish scenarios say about 084990?
Our models span a range for Helixmith Co. Ltd: cautious scenario 756.32 KRW, base 774.11 KRW, optimistic 802.73 KRW per share (as of Sep 24, 2026, price 2,995 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Helixmith Co. Ltd (084990)?
Balance-sheet figures for Helixmith Co. Ltd (as of Sep 24, 2026): debt of 0.00 per unit of equity. They feed the Quality Score of 50/100, which measures business quality independently of the share price.
How far is 084990 from its 52-week high?
Helixmith Co. Ltd trades at 2,995 KRW, about 68% below its 52-week high of 9,470 KRW and 7% above the low of 2,805 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 774.11 KRW is for.
Which stocks are comparable to Helixmith Co. Ltd?
From the same area (Consumer Non-Cyclicals) we also value FB, URC, MONDE, CNPF, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Helixmith Co. Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price 2,995 KRW, calculated fair value 774.11 KRW (−74%), Quality Score 50/100, from 2 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 084990 calculated?
We run Helixmith Co. Ltd through 2 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 774.11 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.2 % above its aggregate fair value. Helixmith Co. Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Helixmith Co. Ltd (084990)?
The closing price on Sep 23, 2026 was 2,995 KRW. Our model-based fair value is 774.11 KRW, about −74% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Helixmith Co. Ltd right now?
The price sits above even our optimistic bull case (802.73 KRW). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (50/100) and above fair value, neither a clear bargain nor a standout compounder. The models converge in a tight band (756.32 KRW to 802.73 KRW), unusually little disagreement for a valuation.
Key figures of Helixmith Co. Ltd
How large is the market capitalisation of Helixmith Co. Ltd (084990)?
The market capitalisation of Helixmith Co. Ltd is 158B KRW (≈ $110M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Helixmith Co. Ltd (084990)?
The price-to-sales ratio of Helixmith Co. Ltd is 54.5 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Helixmith Co. Ltd (084990)?
The net margin of Helixmith Co. Ltd is −16.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Helixmith Co. Ltd (084990)?
The return on equity (ROE) of Helixmith Co. Ltd is −803% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Helixmith Co. Ltd (084990)?
On an EBIT basis the return on assets of Helixmith Co. Ltd is −21.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Helixmith Co. Ltd (084990)?
The operating margin of Helixmith Co. Ltd is −1,924% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Helixmith Co. Ltd (084990)?
Revenue at Helixmith Co. Ltd is growing +18.1% versus a year earlier (3y avg −2.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Helixmith Co. Ltd (084990) generate?
The free cash flow of Helixmith Co. Ltd is −7.2B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Helixmith Co. Ltd (084990) carry?
The net debt of Helixmith Co. Ltd is 69.6B KRW (fiscal year 2019). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Helixmith Co. Ltd in the live analysis
One click puts Helixmith Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
